Key result
Intravenous rtPA safely improves NIHSS by 8 points in a stroke from left atrial myxoma.
Case Report (n=1)
No
Cardiac myxomas account for less than 1% of all ischemic strokes but should be considered in the differential diagnosis of young patients presenting with stroke.
Supports considering myxoma in select atypical strokes; case reports leave population incidence and screening strategies open.
Background: Cardiac myxomas are a potential source of emboli to the brain and elsewhere in the vascular tree.Myxomas are the most common benign primary cardiac tumor in adults.The commonest location of cardiac myxomas is in the left atrium followed by the right atrium and the remainder develops in the ventricles and rarely in the heart valves.Embolic events occur in approximately 40-50% of patients with myxomas.Crebrovascular strokes secondary to myxomas account for less than 1% of all ischemic strokes but should be considered in the differential diagnosis of patients with stroke in young.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (2015) conducted a case report in Cardioembolic stroke secondary to atrial myxoma (n=1). Intravenous recombinant tissue plasminogen activator (IV rtPA) was evaluated on Clinical improvement (NIHSS score). Intravenous rtPA successfully treated an acute ischemic stroke secondary to a left atrial myxoma in a 42-year-old female, improving her NIHSS from 21 to 13 at 1 month without hemorrhagic transformation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: